Compare AMETEK, Inc. (AME) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AMETEK, Inc. vs TG Therapeutics Inc — how do they compare? AMETEK, Inc. trades at $258.86 (market cap $58.76B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: AMETEK, Inc. is far larger — about 7.7× TG Therapeutics Inc's market cap, and AMETEK, Inc. pays a 0.53% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| AME | TGTX | |
|---|---|---|
Market Cap | $58.76B | $7.64B |
Sector | Industrials | Health |
52-Week High | $258.52 | $59.06 |
52-Week Low | $179.28 | $26.94 |
Enterprise Value | $60.30B | $7.84B |
Dividend Yield | 0.53% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AME trades at $258.62, up 2.27% today, with a bullish technical signal and strong earnings momentum after beating Q2 2026 EPS estimates. The company reported record Q2 results and raised full-year guidance, supported by robust revenue growth and a 20.04% net income margin. Analysts maintain a consensus buy rating with a $281.86 price target, reflecting optimism about its 3D printing and electronics testing segments.
The outlook is positive given consistent earnings beats and upward guidance, but risks include high valuation multiples (P/E 37.47) and exposure to macroeconomic volatility. Institutional sentiment remains strong, with no sell ratings among 30 analysts, though the stock's proximity to resistance at $261 warrants caution for near-term entries.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AMETEK, Inc.
Ametek is a diversified industrial conglomerate with over $6 billion in sales. The firm operates through an electronic instruments group and an electromechanical group. EIG designs and manufactures differentiated and advanced instruments for the process, aerospace, power, and industrial end markets. EMG is a focused, niche supplier of highly engineered automation solutions, thermal management systems, specialty metals, and electrical interconnects, among other products. About half of the firm's sales are made in the United States. The firm's asset-light strategy in place for nearly two decades emphasizes growth through acquisitions, new product development through research and development, driving operational efficiencies, and global and market expansion.
Read more on AME →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
